AU2002224354A1 - Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers - Google Patents
Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriersInfo
- Publication number
- AU2002224354A1 AU2002224354A1 AU2002224354A AU2435402A AU2002224354A1 AU 2002224354 A1 AU2002224354 A1 AU 2002224354A1 AU 2002224354 A AU2002224354 A AU 2002224354A AU 2435402 A AU2435402 A AU 2435402A AU 2002224354 A1 AU2002224354 A1 AU 2002224354A1
- Authority
- AU
- Australia
- Prior art keywords
- phospholipase
- compositions
- methods
- paracellular permeability
- epithelial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title abstract 4
- 230000035699 permeability Effects 0.000 title abstract 4
- 230000002708 enhancing effect Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003371 phospholipase C inhibitor Substances 0.000 title abstract 3
- 230000008497 endothelial barrier function Effects 0.000 title 1
- 230000004890 epithelial barrier function Effects 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 abstract 3
- 229940124034 Phospholipase C inhibitor Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23932800P | 2000-10-10 | 2000-10-10 | |
US60/239,328 | 2000-10-10 | ||
PCT/US2001/031501 WO2002030408A2 (en) | 2000-10-10 | 2001-10-10 | Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002224354A1 true AU2002224354A1 (en) | 2002-04-22 |
Family
ID=22901681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002224354A Abandoned AU2002224354A1 (en) | 2000-10-10 | 2001-10-10 | Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
Country Status (11)
Country | Link |
---|---|
US (1) | US7713949B2 (ja) |
EP (2) | EP1379235B1 (ja) |
JP (1) | JP2004532795A (ja) |
AT (2) | ATE496619T1 (ja) |
AU (1) | AU2002224354A1 (ja) |
CA (1) | CA2425215C (ja) |
DE (2) | DE60143975D1 (ja) |
DK (2) | DK1379235T3 (ja) |
ES (1) | ES2276847T3 (ja) |
MX (1) | MXPA03002934A (ja) |
WO (1) | WO2002030408A2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1566447A1 (en) * | 2004-02-20 | 2005-08-24 | Aventis Pharma Deutschland GmbH | Glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C regulation |
US20110046079A1 (en) * | 2008-01-16 | 2011-02-24 | Mullin James M | Use of Proton Pump Inhibitors as Drug Delivery Adjuvants |
EP2506711B1 (en) | 2009-12-03 | 2019-04-03 | OPKO Health, Inc. | Hypersulfated disaccharide formulations |
CN108069929B (zh) * | 2016-11-18 | 2021-06-15 | 中国科学院大连化学物理研究所 | 3-取代香豆素类衍生物及应用和gpr35受体的激动剂 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1511653A (en) * | 1974-04-16 | 1978-05-24 | Wellcome Found | Anthelmintic compositions and use |
US4199507A (en) | 1977-05-05 | 1980-04-22 | The Upjohn Company | Oxazole [2,3-c]-coumarin |
US5373095A (en) | 1985-10-18 | 1994-12-13 | The Upjohn Company | Steroid compounds |
WO1987002367A2 (en) | 1985-10-18 | 1987-04-23 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
US5001234A (en) | 1987-04-16 | 1991-03-19 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
US5306830A (en) | 1989-04-27 | 1994-04-26 | The Upjohn Company | Substituted 3-amino chromans |
US5144045A (en) | 1990-11-13 | 1992-09-01 | American Cyanamid Company | Phosphocholine derivative inhibitors of phospholipase A2 |
US5208223A (en) | 1990-11-13 | 1993-05-04 | American Cyanamid Company | Phosphocholine derivative inhibitors of phospholipase A2 |
US5234933A (en) * | 1991-10-31 | 1993-08-10 | Board Of Governors Of Wayne State University And Vanderbilt University | Cyclic hydroxamic acids |
US5580956A (en) | 1992-03-11 | 1996-12-03 | Kyowa Hakko Kogyo Co., Ltd. | Phospholipase C-inhibiting peptides |
DE4210332C1 (ja) * | 1992-03-30 | 1993-07-15 | Gruenenthal Gmbh, 5100 Aachen, De | |
US5238832A (en) | 1992-06-08 | 1993-08-24 | Board Of Governors Of Wayne State University | Aryl aliphatic acids |
AU5076293A (en) | 1992-12-04 | 1994-06-16 | F. Hoffmann-La Roche Ag | Hispidospermidin |
US5360815A (en) | 1993-06-23 | 1994-11-01 | Merck Frosst Canada, Inc. | Heteroaryl cinnamic acids as inhibitors of leukotriene biosynthesis |
US5519163A (en) | 1993-10-15 | 1996-05-21 | Merck & Co., Inc. | Inhibitors of phosphoinositide-specific phospholipase C |
US5942246A (en) | 1996-02-16 | 1999-08-24 | The Liposome Company, Inc. | Etherlipid containing multiple lipid liposomes |
DE69739482D1 (de) * | 1996-09-11 | 2009-08-13 | Elizabeth Shanahan-Prendergast | Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen |
IL137672A0 (en) * | 2000-08-03 | 2001-10-31 | Dpharm Ltd | Derivatives of branched-chain lipophilic molecules and uses thereof |
-
2001
- 2001-10-10 MX MXPA03002934A patent/MXPA03002934A/es unknown
- 2001-10-10 DK DK01986603T patent/DK1379235T3/da active
- 2001-10-10 DE DE60143975T patent/DE60143975D1/de not_active Expired - Lifetime
- 2001-10-10 AU AU2002224354A patent/AU2002224354A1/en not_active Abandoned
- 2001-10-10 US US09/974,519 patent/US7713949B2/en not_active Expired - Fee Related
- 2001-10-10 DK DK06119516.0T patent/DK1754480T3/da active
- 2001-10-10 EP EP01986603A patent/EP1379235B1/en not_active Expired - Lifetime
- 2001-10-10 JP JP2002533851A patent/JP2004532795A/ja active Pending
- 2001-10-10 CA CA002425215A patent/CA2425215C/en not_active Expired - Fee Related
- 2001-10-10 ES ES01986603T patent/ES2276847T3/es not_active Expired - Lifetime
- 2001-10-10 AT AT06119516T patent/ATE496619T1/de not_active IP Right Cessation
- 2001-10-10 EP EP06119516A patent/EP1754480B1/en not_active Expired - Lifetime
- 2001-10-10 AT AT01986603T patent/ATE348622T1/de not_active IP Right Cessation
- 2001-10-10 DE DE60125420T patent/DE60125420T2/de not_active Expired - Fee Related
- 2001-10-10 WO PCT/US2001/031501 patent/WO2002030408A2/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
MXPA03002934A (es) | 2004-05-04 |
EP1754480A3 (en) | 2007-05-09 |
DE60143975D1 (de) | 2011-03-10 |
CA2425215A1 (en) | 2002-04-18 |
JP2004532795A (ja) | 2004-10-28 |
DE60125420T2 (de) | 2007-09-27 |
ATE348622T1 (de) | 2007-01-15 |
US7713949B2 (en) | 2010-05-11 |
DK1754480T3 (da) | 2011-05-16 |
EP1379235B1 (en) | 2006-12-20 |
EP1754480A2 (en) | 2007-02-21 |
EP1754480B1 (en) | 2011-01-26 |
ATE496619T1 (de) | 2011-02-15 |
EP1379235A2 (en) | 2004-01-14 |
ES2276847T3 (es) | 2007-07-01 |
WO2002030408A3 (en) | 2003-11-06 |
DK1379235T3 (da) | 2007-01-29 |
CA2425215C (en) | 2009-12-29 |
US20020115641A1 (en) | 2002-08-22 |
DE60125420D1 (de) | 2007-02-01 |
WO2002030408A2 (en) | 2002-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE04990B1 (et) | HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod | |
PL373903A1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
WO2003032914A3 (en) | Methods for treating substance abuse with cholinesterase inhibitors | |
SE9803710L (sv) | Användning av vissa substanser för behandling av nervrotsskador | |
HUS1200030I1 (hu) | Dipeptidil peptidáz IV ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás elõállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
FR14C0054I1 (fr) | C-aryl glucosides en tant qu'inhibiteurs de sglt-2 et methode correspondante | |
BR0212042A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto | |
BRPI0407993B8 (pt) | compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos | |
WO1999005096A3 (en) | Urokinase inhibitors | |
AU2002241736A1 (en) | Method for preventing or treating pain by administering an endothelin antagonist | |
DK1187803T3 (da) | Amorfe salpetersyreestere og deres farmaceutiske sammensætninger | |
DE50115451D1 (de) | Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl | |
AU1023497A (en) | Tissue factor - kunitz domain fusion proteins as factor viia inhibitors | |
AU2002224354A1 (en) | Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers | |
WO2001070255A3 (en) | Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor | |
NO20051261L (no) | Morfin-6-glukuronidsalt | |
WO2001087281A3 (en) | Method for enhancing cognitive function | |
AU2001246388A1 (en) | Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine | |
WO2002030445A3 (en) | Fibrinogen plus a non-plasmin-acting fibrinolysis inhibitor for the reduction or prevention of adhesion formation | |
PT1276722E (pt) | Inibidores de naftamidina-uroquinase | |
HK1061647A1 (en) | Pharmaceutical compositions of rapmycins | |
DE69824862D1 (de) | Zusammenstellungen zur verbesserten wundheilung | |
PT769945E (pt) | Metodos para cicratizacao ossea e consolidacao de fracturas | |
WO2004054522A3 (de) | Milde tensidzusammensetzungen | |
WO2003057154A3 (en) | Naaladase inhibitors for treating huntington's disease |